AT-35 INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL

BACKGROUND: Kinase inhibitors targeting driver mutations are active in several cancers, but have shown only minimal activity against malignant gliomas (MGs). Inadequate drug delivery when administered at the maximum tolerated daily dose may contribute to limited efficacy. Transient inhibition of onc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lassman, Andrew, Grommes, Christian, Panageas, Katherine, Iwamoto, Fabio, DeAngelis, Lisa, Kaley, Thomas, Gavrilovic, Igor, Pentsova, Elena, Omuro, Antonio, Corpuz, Christina, Briggs, Samuel, Otap, Daniel, Qin, Weige, Cross, Justin, Mellinghoff, Ingo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217814/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.35
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados